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Systemic sclerosis (SSc) is an autoimmune condition characterized by the deposition of excess collagen in skin and internal organs. The pathogenesis of systemic sclerosis SSc is complex and incompletely understood; however, immune activation (T-cell activation and cytokine release) is thought to be an early factor, followed by tissue fibroblast activation and subsequent excess collagen deposition. 1 A subset of patients with a high mortality rate can be identified on the basis of rapidly progressive disease, an elevated ESR, and renal or pulmonary disease. 2 Although no proven effective treatment exists, several phase II trials suggest that high-dose immunosuppressive therapy with autologous stem cell rescue (HSCT) may be beneficial in arresting disease progression with improvement in skin and disease scores. [3] [4] [5] A 23-year-old woman presented in August 2001 with widespread arthralgias, generalized skin tightening, marked lethargy and 10 kg of weight gain due to gross oedema. The arthralgias and myalgias were followed by marked skin tightening, and a diagnosis of diffuse systemic sclerosis was made. She developed symptoms of dyspepsia and endoscopy confirmed gastro-oesophageal reflux disease. Respiratory function tests revealed a DLCO of 69%, renal function was normal, as was a transthoracic echocardiogram. Initially, she was treated with methotrexate and corticosteroids with minimal effect. She subsequently experienced a partial but brief response to monthly pulse cyclophosphamide (6 Â 750 mg) and cyclosporine. She was referred for high-dose immunosuppression followed by stem cell rescue, and peripheral blood stem cells (77 Â 106/ kg) were mobilized with GCSF following her fourth course of cyclophosphamide. She was admitted electively in October 2002 for the procedure. Examination revealed diffuse scleroderma involving her arms (sclerodactyly and calcinosis), legs and most of her trunk, with a modified Rodnan skin score of 27/51. She had occasional crepitations in her lungs and her cardiovascular examination was normal (BP 100/70). Her medications on admission were omeprazole 40 mg daily and captopril 12.5 mg twice daily; the latter was ceased due to her blood pressure on admission. She was commenced on four daily doses of cyclophosphamide (50 mg/kg), two doses of equine ATG (10 mg/kg) and two doses of methylprednisolone (50 mg) prior to her unmanipulated stem cell infusion (38 Â 10 6 CD34 cells/kg). Following the stem cell infusion, she was given a further two doses of ATG (D þ 1, D þ 3) and tapering doses of methylprednisolone. Her post-transplant course was complicated on day 5 by worsening of her arthralgias and myalgias, blurring of vision and fevers to 391C, thought to be an ATG-related serum sickness. The fevers were unresponsive to empirical antibiotic therapy or neutrophil engraftment on day 10, but responded promptly to 1 mg/kg methylprednisolone and simple analgesia. At 1 week after the stem cell infusion, the patient was noted to have a raised LDH (797 U/l), which steadily rose over the next week to 2043 U/l, during which time the serum creatinine rose from 0.05 to 0.08 mmol/l (Figure 1 ). The peripheral blood smear revealed fragmented red cells consistent with intravascular haemolysis, but the haemoglobin and platelet count were rising in keeping with engraftment. The serum bilirubin and coagulation studies were normal. On day þ 25, deterioration in renal function progressed with a creatinine of 0.15 mmol/l (previously 0.06), a urea content of 16.6 mmol/l (previously 5.5) and a glomerular filtration rate of 45 ml/min (previously 90 ml/ min). Blood pressure had now increased to 140/80 and ACE inhibitor therapy was recommenced. Both a renal ultrasound and phase-contrast microscopy of mid-stream urine were normal. A urinary protein of 1.38 g/l (previously 0.4 g/l) was the only abnormality in the urine biochemistry. A renal biopsy was performed and light microscopy suggested scleroderma renal disease (fibrinoid necrosis) with evidence of microangiopathic haemolysis and tubular damage was also noted (Figure 2) . These results were interpreted as evidence of scleroderma renal crisis (SRC) possibly precipitated by the prednisolone or the serum sickness illness. Systolic hypertension (4150 mmHg) persisted despite captopril 50 mg tds, irbersartan 150 mg daily, felodipine 10 mg daily and prazosin 0.5 mg tds. Her renal function continued to decline (creatinine 0.51 mmol/l) and she was commenced on haemodialysis on day þ 44 and subsequently discharged on continuous ambulatory peritoneal dialysis (CAPD). She remained on CAPD until she regained adequate renal function on day þ 117. Since day þ 60, the patient has experienced decreasing myalgia and arthralgia and a reversing of skin thickening in her neck, legs and arms. Review at 7 and 15 months followup has revealed marked clinical improvement in her musculoskeletal disease status as measured by skin scores, HAQ, CRP and visual analogue scales (see Table 1 ). She is now only on Ibersatan, contemplating a return to work and has a markedly improved quality of life. Her serum creatinine is 0.09 mmol/l, the serum LDH is normal with no fragmented cells on her peripheral blood film and she is normotensive. This is the first reported case of SRC complicating an HSCT procedure. Importantly, the microangiopathy changes occurred prior to the SRC perhaps as a consequence of red cells being fragmented during passage through constricted vessels of the kidney. Although this is unproven, it is supported by the fact that the rise in LDH in conjunction with red cell fragmentation peaked before a significant rise in the creatinine (Figure 1 ). Scleroderma renal crisis may present as a thrombotic thrombocytopenic purpura (TTP)-like syndrome, with renal insufficiency and microangiopathic haemolytic anaemia. 6, 7 Although both SSc and TTP are associated with an occlusive microangiopathy, the co-existence of both conditions is rare. SRC and TTP have similar clinical and laboratory features, but several characteristics such as the lack of neurological abnormalities and thrombocytopenia suggest this was a microangiopathic process associated with SRC rather than TTP. The precipitant of the SRC remains unclear; however, prednisone, used in this case to prevent serum sickness, has been reported to cause the crisis. 8 Despite this setback, the patient has continued to demonstrate major clinical improvement, demonstrating improving skin scores and HAQ scores between 6 and 15 months as reported in other studies. 3, 4 This case illustrates the importance of monitoring blood pressure and renal function in scleroderma patients undergoing HSCT. Regular review of the blood film and serum LDH should be considered in these patients to circumvent deterioration in renal function and SRC. It may be the case that patients undergoing HSCT require maximization of ACE inhibitor therapy prior to transplant. The importance of a biopsy in the diagnosis of SRC should also be noted, particularly given the many causes of SRC in this clinical setting, including acute tubular necrosis, in which case ACE therapy may be contraindicated. This case also demonstrates the significant persistent responses attained in these patients after HSCT. The recently commenced Autologous Stem Cell Transplantation International Scleroderma (ASTIS) trial will help to delineate the role for this procedure in the management of these patients. 
